EDLUND, Per et al. Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1. Acta Oncologica, [S. l.], v. 50, n. 3, p. 329–337, 2011. DOI: 10.3109/0284186X.2011.554435. Disponível em: https://medicaljournalssweden.se/actaoncologica/article/view/31961. Acesso em: 30 apr. 2026.